Tevogen Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Tevogen Bio Holdings Inc. Announcement

WARREN, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today that on October 28, 2024, it received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement (the “Minimum Bid Price Requirement”), as set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Global Market.

Implications of Regaining Compliance

This announcement is significant for Tevogen Bio as it shows that the company is meeting the necessary requirements for continued listing on the Nasdaq Global Market. Regaining compliance with the minimum bid price requirement is a positive development for the company, signaling stability and potential growth in the future.

By meeting this requirement, Tevogen Bio can maintain its listing on the Nasdaq Global Market, which can provide increased visibility and liquidity for the company’s stock. This can attract more investors and help support the company’s growth and development efforts.

How It Will Affect Me

As a shareholder or potential investor in Tevogen Bio, the news of the company regaining compliance with the Nasdaq minimum bid price requirement is reassuring. It demonstrates that the company is meeting regulatory standards and is committed to upholding its listing on the Nasdaq Global Market. This can instill confidence in investors and potentially lead to increased interest in the company’s stock.

How It Will Affect the World

In a broader sense, Tevogen Bio’s compliance with the Nasdaq minimum bid price requirement reflects positively on the biotech industry as a whole. It highlights the innovative work being done in developing immunotherapy treatments for infectious diseases and cancers, and the importance of these advancements in improving global health outcomes.

Conclusion

In conclusion, Tevogen Bio’s announcement of regaining compliance with the Nasdaq minimum bid price requirement is a significant milestone for the company. It demonstrates their commitment to meeting regulatory standards and provides a strong foundation for future growth and development. As both a shareholder and a member of the global community, this news is encouraging and underscores the importance of biotech companies in advancing healthcare and improving quality of life for people around the world.